SPÓŁKA AKCYJNA
Netrix
Netrix Spółka Akcyjna
SPÓŁKA AKCYJNA
Netrix Spółka Akcyjna
Netrix Spółka Akcyjna (KRS 0000573573, NIP 7123299856) is a Polish company, headquartered in Lublin, Lubelskie voivodeship. Netrix operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since September 1, 2015. Netrix's most recently reported net revenue was 29.9 M PLN for 2024.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Credibility rating
39.8 / 100
Poor credibility
Insolvency risk
Moderate
Significant formal threat
Closure risk
16
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/11 yrs
Board changes
1
1/11 yrs
PKD changes
1
1/11 yrs
Name changes
0
0/11 yrs
Data from 11 years of registry activity.
Payment reliability score from 2023–2024
Current: E (40/100)
Trend: deteriorating (-7.4 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Standard limit from 2023–2024
Current: 721.3 K PLN
Safe: 122.6 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Founded
September 1, 2015
10 years in operation
Legal form
SPÓŁKA AKCYJNA
Registry: RejP
Headquarters
LUBLIN
LUBELSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
200.0 K PLN
Shareholders
1
shareholder
Board
2 people
Sup. board: 3
Filed years
2 years
2023–2024
Registry entries
52
latest: July 10, 2026
Revenue
29.9 M PLN
2024
Net profit
479.0 K PLN
2024
Assets
68.4 M PLN
2024
Equity
18.3 M PLN
2024
EBITDA
5.9 M PLN
2024
Valuation
9.3 M PLN
Medium confidence
Rate business credibility - Netrix.
No ratings
News
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
Netrix's board has 2 members.
Latest reporting year
2025
Available years
10
Filing entries
0
20 historical registry entries for Netrix
Change in Section 1 (basic data)
LU.VI NS-REJ.KRS/4306/24/7
Filing documents submitted (4 documents)
Change in Section 1 (basic data)
LU.VI NS-REJ.KRS/4306/24/7/ADE
Filing documents submitted (4 documents)
Filing documents submitted (4 documents)
Competing companies or those operating in the same market segment as Netrix (in Lublin, industry: Research and development).
WARSZAWA· Research and development
Revenue 2023: 94.7 M PLN
ŁÓDŹ· Research and development
Revenue 2024: 76.1 M PLN
WARSZAWA· Research and development
Revenue 2025: 71.2 M PLN
MIELEC· Research and development
Revenue 2024: 37.7 M PLN
TORUŃ· Research and development
Revenue 2024: 21.5 M PLN
LUBLIN· Research and development
Revenue 2025: 10.0 M PLN
